Health in the USA, promises to supply a variety of relevant transgenic mouse models for the cardiovascular system, enabling optogenetic manipulation and imaging. Furthermore, new gene editing techniques open the door to affordable commercial generation of desired transgenic mice or even larger transgenic animals in a shorter time frame. Although the transgenic approach is highly valuable for mechanistic studies, translational relevance requires the pursuit of alternative (non-transgenic) ways for genetic manipulation. Quick and effective cell-mediated, 9 adenoviral, or lentiviral expression of optical actuators in neonatal and adult cardiomyocytes has been shown in vitro, 10 -13 but these approaches have not been demonstrated in vivo. While optogenetic interrogation of the mammalian brain in freely moving animals has become common place, comparable in vivo optogenetic manipulation of cardiac function is yet to be realized; a robust way to inscribe light sensitivity in the intact heart or heart structures of interest is a requisite step towards this goal.
Sasse's laboratory first demonstrated optogenetic manipulation of the mammalian heart using transgenic mice.
14 Following on this pioneering work, in this issue, they 15 16 Vogt et al. 15 achieve an impressive, almost exclusively cardiac-specific, expression despite the use of a ubiquitous (CAG) promoter. While the wild-type AAVs feature unique site-specific integration in the genome, 17 the AAV vectors devoid of viral genes, as used in this study, do not integrate in the genome but, remarkably, retain coveted long-term expression (10 months demonstrated here, 10 years seen in a patient 18 ), seemingly without disruption of other genes. The low immunogenicity of AAVs that makes them an attractive tool for gene therapy in humans 19 was also confirmed here, with no inflammation reported. The advantages of the reported minimally invasive method, compared with transgenic approaches for cardiac optogenetics, include: (i) easy scalability to larger animals (including established cardiac disease models), where in vivo insertion of optical conduits for stimulation or imaging is feasible; 20 (ii) robust combination of genetic manipulations in the same animal, e.g. combining spectrally compatible actuators and sensors, or combining opsins with depolarizing and hyperpolarizing effects for bi-directional control by light; and, importantly, (iii) the approach provides a path to potential clinical translation. Considering the success of AAV-based clinical trials, including the CUPID trial 21 for heart failure patients, this is an important and relevant step, even if basic science applications are the main current focus of this technology. The AAV-mediated optogenetic transformation is not without problems. Naturally occurring neutralizing antibodies make this approach somewhat subject-specific, though out of all 13 known serotypes, encountering antibodies against AAV9 is the least likely (found in ,20% of humans). 22 This may have been a contributing factor in the lack of response in 26% of the studied animals by Vogt et al. 15 Furthermore, specificity of expression is dose-dependent, e.g. viral doses higher than the employed here (2 × 10 11 viral particles per mouse)
can yield non-myocardial expression for AAV9 in the diaphragm, liver, and skeletal muscle, and can even cross the blood -brain barrier to infect neurons and astrocytes, 23 which may or may not cause side effects. Cell-and tissue-specific promoters, combined with serotype tropism, can alleviate these problems but often at the cost of weaker expression. Interestingly, AAV9 has been reported to localize preferentially to ischaemic areas (border zone), 24 which can be leveraged for region targeting in cardiac applications. was required for optical pacing in the ventricles. This number represents a relevant constraint for investigative purposes, i.e. to allow robust optogenetic perturbation of electrical activity at an arbitrary ventricular location, with a relatively small optical conduit. However, the creation of a space-localized optical biological pacemaker can be achieved by a much smaller number of optogenetically transformed cells (by gene or cell delivery), as long as the light-responsive region is consolidated, to provide enough charge for driving the myocardium. Following the demonstration of this elegant approach for minimally invasive and stable optogenetic transformation of the heart, the next logical step is to take full advantage of the cell specificity of optogenetic targeting to strategic structures, e.g. sinoatrial node, atrioventricular node, or His bundle, or for dissection of neural -cardiac interactions, 25 as reported recently. Outstanding practical challenges to be addressed concern the light delivery to a desired cardiac location in the intact animal, for true in vivo optogenetic actuation, as commonly done in the brain. Two main approaches to optically stimulate and optically record appear feasible: endoscopically 20 using fibre optics and borrowing from microendoscopy applications in neuroscience, or through the implantation of miniaturized devices. 26 Additionally, spectral challenges also need to be resolved, i.e. red-shifted opsins are desirable for deeper penetration. However, the open-chest experiments by Vogt et al. suggest that for optical actuation, light absorption by haemoglobin may be an addressable problem, once the light is guided to the myocardial location. In summary, Vogt et al. have demonstrated that making the heart sense light can be 'easy'; yet, bringing the light to the heart still faces further challenges in vivo. This work represents an important new development-the first experimental model for cardiac optogenetics that goes beyond in vitro and transgenic animal approaches. Such a model presents new opportunities to study the origin and control of cardiac arrhythmias by precise optical perturbations in vivo. Furthermore, the simplicity and the impressive reported efficiency of the method make it attractive for a much wider range of applications (beyond optogenetics) for gene delivery to the heart.
